Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCTURUS THERAPEUTICS HOLDINGS INC.

(ARCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

11/22/2021 | 08:10am EST

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that members of the Company’s management team will be participating in the Piper Sandler’s 33rd Annual Virtual Healthcare Conference and investor meetings between November 30, 2021 and December 02, 2021. A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22 at 10:00 a.m. ET.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis along with partnered programs including glycogen storage disease type III, hepatitis B virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.


ę Business Wire 2021
All news about ARCTURUS THERAPEUTICS HOLDINGS INC.
01/26HC Wainwright Adjusts Price Target on Arcturus Therapeutics Holdings to $33 From $47, M..
MT
01/25Arcturus Says Its COVID-19 Vaccines Yielded 'Robust' Increase in Neutralizing Antibody ..
MT
01/25Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Respo..
BU
01/25Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Respo..
CI
01/24Arcturus Therapeutics Says Its COVID-19 Vaccine Candidates Showed Strong Antibody Respo..
MT
01/24Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
01/24Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial De..
BU
01/21Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
01/11ARCTURUS THERAPEUTICS HOLDINGS INC. : Regulation FD Disclosure (form 8-K)
AQ
2021Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
More news
Analyst Recommendations on ARCTURUS THERAPEUTICS HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 21,4 M - -
Net income 2021 -211 M - -
Net cash 2021 306 M - -
P/E ratio 2021 -2,72x
Yield 2021 -
Capitalization 566 M 566 M -
EV / Sales 2021 12,2x
EV / Sales 2022 1,66x
Nbr of Employees 118
Free-Float 86,1%
Chart ARCTURUS THERAPEUTICS HOLDINGS INC.
Duration : Period :
Arcturus Therapeutics Holdings Inc. Technical Analysis Chart | ARCT | US03969T1097 | MarketScreener
Technical analysis trends ARCTURUS THERAPEUTICS HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 21,48 $
Average target price 83,45 $
Spread / Average Target 289%
EPS Revisions
Managers and Directors
Joseph E. Payne President, Chief Executive Officer & Director
Andrew H. Sassine Chief Financial Officer & Director
Peter C. Farrell Chairman
Padmanabh Chivukula Secretary, Chief Operating & Scientific Officer
Steven G. Hughes Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARCTURUS THERAPEUTICS HOLDINGS INC.-41.96%619
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601